Project Grant HT94252510564
Award Date
8/15/25
Completion Date
8/14/28
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...
The Defense Health Agency awarded a $1.1 million project grant to the University of Texas Southwestern Medical Center in Dallas, Texas, to support research under the Military Medical Research and Development program. The three-year award beginning in June 2023 will fund the development of a multifunctional immunotherapy nanoparticle to enable innate immunotherapy for kidney cancer. As the prime awardee, UT Southwestern will leverage its expertise in oncology and immunology to advance this...
The Defense Health Agency awarded a $492,927 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas to conduct research on leveraging biophysicochemical motifs in T-cell receptor antigen binding regions and antigen co-occurrence to predict response to immune checkpoint inhibitors. This 3-year grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform health...
This federal Project Grant award of $505,071.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The University of Texas M.D. Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award period runs from February 15, 2025 to February 14, 2028. The Military Medical Research and Development program funds diverse biomedical research...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $766,965 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on June 30, 2024. The grant supports a 3-year research project to develop new methods for targeting kidney cancer tumors in order to improve immunotherapy outcomes. The research aims to identify tumor surface biomarkers that can be leveraged to enhance the effectiveness of cancer...
The federal Project Grant award in the amount of $1,312,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to The University of Texas Southwestern Medical Center in Dallas, TX to "DEFINE THE HUMORAL IMMUNITY IN KIDNEY CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS." The grant has a performance period from September 1, 2024 to August 31, 2028 and supports advanced biomedical research...
The University of Texas Southwestern Medical Center (UT Southwestern) has been awarded a Project Grant for $1,180,962.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 30, 2024, will support a research project titled "TUMOR SURFACE BIOMARKER-INDEPENDENT TARGETING OF KIDNEY CANCER TO IMPROVE IMMUNOTHERAPY" over a performance period ending on June 29, 2027. The grant funding will enable UT...
The University of Texas MD Anderson Cancer Center was awarded a $932,350 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to develop an in situ tumor vaccine to stimulate antitumor immunity against breast cancer. The 3-year grant, awarded on August 15, 2025, supports advanced biomedical research focused on innovative solutions to critical health challenges facing military personnel and the broader public. The project aims to...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...